PFIZER INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
PFE$29.36+0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Total Revenues––Selected Product Discussion
Biopharma
| Revenue | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (MILLIONS) · Year Ended Dec. 31, · % Change | |||||||||
| Product · GlobalRevenues · Region · 2024 · 2023 · Total · Oper. · Operational Results Commentary | |||||||||
| Eliquis | $7,366Up 10%(operationally) | U.S. | $4,803 | $4,228 | 14 | Growth driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to loss of patent-based exclusivity and generic competition in certain international markets. | |||
| Int’l. | 2,563 | 2,519 | 2 | 3 | |||||
| Worldwide | $7,366 | $6,747 | 9 | 10 | |||||
| Prevnar family | $6,411Down 1% (operationally) | U.S. | $4,233 | $4,265 | (1) | Declines driven by fewer adult vaccinations in the U.S. and lower pediatric indication sales in most international developed markets and certain emerging markets, partially offset by growth in the pediatric indication in the U.S. reflecting recovered market share as a result of the Prevnar 20 launch in 2023, as well as strong uptake of the adult indication in certain international markets. | |||
| Int’l. | 2,178 | 2,236 | (3) | (1) | |||||
| Worldwide | $6,411 | $6,501 | (1) | (1) | |||||
| Revenue | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (MILLIONS) · Year Ended Dec. 31, · % Change | |||||||||||||
| Product · GlobalRevenues · Region · 2024 · 2023 · Total · Oper. · Operational Results Commentary | |||||||||||||
| Paxlovid | $5,716Up *(operationally) | U.S. | $4,616 | $(1,289) | * | Growth primarily driven by:• a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023 (see Note 17C);• a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023; and• $442 million from the one-time contractual delivery of treatment courses to the U.S. SNS in the third quarter of 2024,partially offset by:• lower contractual deliveries in most international markets as a result of the transition to traditional commercial market sales; and• lower demand globally, largely in China due to the non-recurrent surge in COVID-19 infection during the first quarter of 2023 and transition to the out-of-pocket market in the second quarter of 2023. | |||||||
| Int’l. | 1,100 | 2,568 | (57) | (57) | |||||||||
| Worldwide | $5,716 | $1,279 | * | * | |||||||||
| Vyndaqel family | $5,451Up 65%(operationally) | U.S. | $3,547 | $1,863 | 90 | Growth largely driven by strong demand with continuing uptake in patient diagnosis, primarily in the U.S. and international developed markets, as well as increased affordability in the U.S. | |||||||
| Int’l. | 1,904 | 1,458 | 31 | 32 | |||||||||
| Worldwide | $5,451 | $3,321 | 64 | 65 | |||||||||
| Comirnaty | $5,353Down 53% (operationally) | U.S. | $2,004 | $2,404 | (17) | Declines largely driven by lower contractual deliveries in international markets as well as a decrease in vaccinations globally. | |||||||
| Int’l. | 3,349 | 8,816 | (62) | (62) | |||||||||
| Worldwide | $5,353 | $11,220 | (52) | (53) | |||||||||
| Ibrance | $4,367Down 8% (operationally) | U.S. | $2,849 | $3,151 | (10) | Declines primarily driven by lower demand due to competitive pressures mainly in the U.S., price decreases in certain international developed markets and generic penetration in certain emerging markets. | |||||||
| Int’l. | 1,518 | 1,602 | (5) | (4) | |||||||||
| Worldwide | $4,367 | $4,753 | (8) | (8) | |||||||||
| Xtandi | $2,039Up 23% (operationally) | U.S. | $2,039 | $1,659 | 23 | Growth largely driven by strong demand due to uptake of the nmCSPC indication following approval in the fourth quarter of 2023 and increased affordability in the U.S. | |||||||
| Int’l. | — | — | — | — | |||||||||
| Worldwide | $2,039 | $1,659 | 23 | 23 | |||||||||
| Padcev | $1,588Up *(operationally) | U.S. | $1,561 | $53 | * | Growth driven by the acquisition of Seagen in the fourth quarter of 2023 as well as strong demand. | |||||||
| Int’l. | 27 | — | * | * | |||||||||
| Worldwide | $1,588 | $53 | * | * | |||||||||
| Nurtec ODT/Vydura | $1,263Up 36%(operationally) | U.S. | $1,193 | $908 | 31 | Growth primarily driven by strong demand in the U.S. and, to a much lesser extent, recent launches in international markets, partially offset by lower net price in the U.S. due to unfavorable changes in channel mix. | |||||||
| Int’l. | 69 | 20 | * | * | |||||||||
| Worldwide | $1,263 | $928 | 36 | 36 | |||||||||
| Xeljanz | $1,168Down 31% (operationally) | U.S. | $680 | $1,154 | (41) | Declines primarily driven by lower demand globally resulting from ongoing shifts in prescribing patterns related to label changes, as well as lower net price in the U.S. and the impact of regulatory exclusivity expiry in Canada. | |||||||
| Int’l. | 488 | 549 | (11) | (9) | |||||||||
| Worldwide | $1,168 | $1,703 | (31) | (31) | |||||||||
| Adcetris | $1,089Up *(operationally) | U.S. | $1,059 | $56 | * | Growth driven by the acquisition of Seagen in the fourth quarter of 2023. | |||||||
| Int’l. | 30 | — | * | * | |||||||||
| Worldwide | $1,089 | $56 | * | * | |||||||||
| Revenue | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (MILLIONS) · Year Ended Dec. 31, · % Change | ||||||||||
| Product · GlobalRevenues · Region · 2024 · 2023 · Total · Oper. · Operational Results Commentary | ||||||||||
| Inlyta | $978Down 5% (operationally) | U.S. | $588 | $642 | (8) | Declines primarily driven by lower demand in the U.S. as well as lower volumes and lower net price in international markets, partially offset by strong growth in China. | ||||
| Int’l. | 391 | 394 | (1) | 1 | ||||||
| Worldwide | $978 | $1,036 | (6) | (5) | ||||||
| Abrysvo | $755Down 15%(operationally) | U.S. | $594 | $888 | (33) | Decline primarily driven by a significant reduction in vaccination rates in the U.S. for the older adult indication, partially offset by strong demand for the maternal indication in the U.S. (launched in December 2023), and launch uptake for both indications in certain international markets. | ||||
| Int’l. | 160 | 2 | * | * | ||||||
| Worldwide | $755 | $890 | (15) | (15) | ||||||
Pfizer CentreOne
| Revenue | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (MILLIONS) · Year Ended Dec. 31, · % Change | ||||||||||
| Operating Segment · GlobalRevenues · Region · 2024 · 2023 · Total · Oper. · Operational Results Commentary | ||||||||||
| PC1 | $1,146Down 10%(operationally) | U.S. | $278 | $352 | (21) | Declines primarily driven by lower manufacturing of divested and other third-party products under manufacturing and supply agreements, partially offset by growth in manufacturing-related services. | ||||
| Int’l. | 868 | 920 | (6) | (5) | ||||||
| Worldwide | $1,146 | $1,272 | (10) | (10) | ||||||
See the Item 1. Business—Patents and Other Intellectual Property Rights section for information regarding the expiration of various patent rights, Note 16 for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above and Note 17C for the primary indications or class of the selected products discussed above.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.